demonmariner t1_ixv22ml wrote
Reply to comment by ogpokemontrainer in A novel medication for hemophilia B has just been approved by the Food and Drug Administration. The treatment is a form of gene therapy, intended to replace a dysfunctional gene that leaves people unable to control their bleeding. by Sariel007
Not quite so uplifting.
Sariel007 OP t1_ixv5kr0 wrote
One dose cure instead of "...patients will undergo regular infusions of their missing clotting factor. Though effective at stopping spontaneous bleeding, these infusions are not a cure and in the most severe cases, people may need to get them every two to three days—a costly and time-consuming measure. "
AinsiSera t1_ixvnosp wrote
I read elsewhere that those treatments easily add up to $100k/month, so honestly $3.5 mil is pretty cost effective competitively.
RO489 t1_ixvt06y wrote
Depending if your insurance/ employer agree. Since insurance is mostly tied to employment in the US, they aren't firing the math of a lifetime cost. I'd imagine single payer would be a no brainer, but if you are an employer, it'll increase everyone's cost.
Another argument in favor of single payer.
scarlet_sage t1_ixvnm9y wrote
It did not appear to be a cure, though it doesn't explain why.
>It also appeared to lower the rate of bleeding problems by 54% in one trial, and it reduced the need for regular infusions of clotting factors....
>it should reduce the frequency of expensive transfusions; they also say that the drug’s effectiveness is expected to last for several years at least.
Viewing a single comment thread. View all comments